Omotesando Helene Clinic Participates in Regenerative Medicine Joint Project in Indonesia as Tokyo Clinical Base for HELENE BIO Group

Omotesando Helene Clinic has joined a joint regenerative medicine project in Indonesia as the Tokyo clinical base for the HELENE BIO Group. On April 27, 2026, the group signed an MOU with PT Star Health Indonesia to explore the establishment of a stem cell clinic and cell processing facility. Based in the BSD City Special Economic Zone (KEK) in Banten Province, the partnership aims to build a regenerative medicine platform that prioritizes safety and ethics.
提携NQ 93/100出典:PR Times

📋 Article Processing Timeline

  • 📰 Published: May 25, 2026 at 21:22
  • 🔍 Collected: May 25, 2026 at 13:01
  • 🤖 AI Analyzed: May 27, 2026 at 15:02 (50h 0m after Collected)
Omotesando Helene Clinic (located in Minato Ward, Tokyo; hereinafter "Omotesando Helene Clinic") is participating in a joint regenerative medicine project in Indonesia as the Tokyo clinical base for the HELENE BIO Group, which operates in the fields of regenerative medicine, advanced cell therapy, and ATMP (Advanced Therapy Medicinal Products).

In connection with this, the HELENE BIO Group signed a Memorandum of Understanding (MOU) on April 27, 2026, with PT Star Health Indonesia (located in Banten Province, Indonesia; hereinafter "Star Health Indonesia"), which operates the StarCare International Clinic in Indonesia, to explore a joint project for establishing a stem cell clinic and cell processing facility in the country.

Under this MOU, both parties plan to discuss the development of clinical facilities for regenerative medicine and a laboratory environment capable of handling cell processing, quality control, storage, and traceability, based at Star Health Indonesia's facilities within the BSD City Special Economic Zone (Kawasan Ekonomi Khusus, hereinafter "KEK") in Banten Province, Indonesia.

This project will explore the feasibility of business commercialization, including the potential for treatments using autologous and allogeneic mesenchymal stem cells (MSCs), in accordance with relevant Indonesian laws, permits, medical ethics, professional regulations, quality standards, as well as requirements for patient consent and data protection.

The commencement of actual medical services and cell processing operations is contingent upon obtaining all necessary permits and meeting requirements for facilities, personnel, quality management systems, and operational readiness.

The HELENE BIO Group is a global network that comprehensively deploys clinical infrastructure, cell processing and manufacturing, quality control, data utilization, cell banking, and international medical collaboration in the fields of regenerative medicine, advanced cell therapy, and ATMP. While respecting the laws, regulations, and medical systems of each region, the group aims to translate insights accumulated in clinical settings into the development of standardized cell therapies and ATMPs, and to improve international medical access.

In recent years, interest in high-level medical care and the wellness sector in Asia has been rising. In Indonesia, there is an expanding need for high-quality medical services, advanced treatment options, and medical infrastructure that meets international standards. As the Tokyo clinical base for the HELENE BIO Group, Omotesando Helene Clinic aims to build a regenerative medicine platform that prioritizes safety, quality, and ethics by connecting the knowledge in regenerative medicine and cell processing accumulated by the clinic with the local medical infrastructure in Indonesia.

FAQ

表参道ヘレネクリニックがインドネシアで参画するプロジェクトとは何ですか?

インドネシアのバンテン州BSD Cityの経済特区(KEK)内における、幹細胞治療クリニックおよび細胞加工施設の設立に向けた共同事業です。

本プロジェクトの目的は何ですか?

インドネシアにおける再生医療プラットフォームの構築を目指し、安全性・品質・倫理性を重視した先進的な治療選択肢と医療基盤を提供することです。

提携先のStar Health Indonesiaはどのような企業ですか?

インドネシア共和国バンテン州においてStarCare International Clinicを運営する企業です。

今後の具体的な協議事項は何ですか?

臨床施設の設立、細胞加工ラボの整備、MSC治療の可能性検討、および許認可や規制上の道筋の整理などを行う予定です。

医療サービスの開始時期はいつですか?

必要なすべての許認可、施設要件、人員体制、品質管理体制および運営準備が整った後に開始されます。